Our leadership team has experience from discovery through to commercialisation
Mr Glyn Edwards was appointed to the Board of Directors as Chief Executive Officer in April 2012. Mr Edwards has a wealth of experience garnered from a thirty-year career in the life sciences industry, during which time he has held a number of senior executive and business development roles.
Prior to joining Summit, he was interim Chief Executive Officer of the UK trade body the BioIndustry Association (BIA) and Chief Executive Officer at Antisoma plc for 13 years, and Vice President of Business Development at Therapeutic Antibodies Ltd. Mr Edwards holds a BSc in biochemistry from Bristol University and an MSc in economics from the London Business School.
Mr Erik Ostrowski was appointed as our Chief Financial Officer in June 2014. Prior to joining Summit Mr Ostrowski served as Vice President of Finance at Organogenesis Inc., a biotechnology company, from 2010 to 2014. Prior to that, Mr Ostrowski worked in investment banking, most recently as a Director with Leerink Partners LLC.
Mr Ostrowski began his career as an accountant with Coopers & Lybrand. Mr Ostrowski received a BS in accounting and economics from Babson College and an MBA from the University of Chicago Booth School of Business.
Dr David Roblin joined as our Chief Operating Officer and President of Research and Development in early 2017 and expanded his role to become Chief Medical Officer in May 2017. Dr Roblin has been acting as a research and development adviser to us since 2014.
Dr Roblin served as the Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute in London from 2014 to 2017. Prior to joining Summit full-time, Dr Roblin was Head of Research, Site Director and Chief Medical Officer for Europe R&D at Pfizer Inc. from 2008 to 2011 and was Head of Therapy Area for Anti-infectives at Bayer AG from 1997 to 1999. After Dr Roblin left Pfizer Inc., he was Chief Medical Officer for a number of biotechnology companies including Creabilis SA where he held that role from 2011 until 2014.
Dr Roblin has a degree in biochemistry from University College London and later qualified in medicine from St George’s Hospital. He is a Fellow of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine. He is an honorary Professor of Medicine at Swansea University and Professor of Translational Medicine at St George’s. He is also a member of the board of directors of MedCity and Destiny Pharma Ltd. Before entering the life sciences industry, Dr Roblin practised medicine for five years.
Dr Elger joined our company in June of 2015. Previously, he served as the Chief Financial Officer and Corporate Development Officer of Genkyotex, Chief Financial Officer of e-Therapeutics plc and Vice President, Marketing and Communications of Antisoma. He earned his PhD in cancer biology from the University of Oxford and BA in medicine also from the University of Oxford.
Dr Vickers joined our company in 2003 and has served as our Chief Scientific Officer, Antimicrobials, since October 2013. During his time at our company, Dr Vickers has worked in a variety of roles involved in the development and management of various antibacterial therapeutic programs, including our antibiotic program for the treatment of CDI.
Prior to joining our company, Dr Vickers undertook postdoctoral research studies with Professor Stephen Davies at the University of Oxford and held a Stipendiary Lectureship in organic chemistry at St. Catherine’s College in Oxford. Dr Vickers received a PhD in organic chemistry from the University of Reading and a BSc in chemistry from King’s College London.
Dr Dave Powell joined Summit from GSK where he served as Director and Head of the Crick-GSK Biomedical LinkLabs, based at GSK’s UK R&D hub at Stevenage, UK, and The Francis Crick Institute in London.
Dr Powell held a number of positions of increasing seniority in his time at GSK. As part of his work there, he participated in antibiotic discovery, assay development, high throughput screening design and implementation, and lead optimisation support. In his most recent role at GSK, he led a collaboration with the Crick Institute, in addition to providing support to GSK’s ‘Discovery Partnerships with Academia’ team which collaborated with academic groups in downstream drug discovery. He was awarded a BSc and MSc from the National University of Ireland Galway, before completing a PhD in biochemistry at Cardiff University.